71
Participants
Start Date
April 30, 2009
Primary Completion Date
November 30, 2009
Study Completion Date
September 30, 2013
Stribild
Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
Atripla
Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
Chelsea Village Medical, New York
Ricky K. Hsu, MD, PC, New York
Dupont Circle Physicians Group, Washington D.C.
Whitman Walker Clinic, Washington D.C.
Capital Medical Associates PC, Washington D.C.
Chase Brexton Health Services, Inc., Baltimore
Rosedale Infectious Diseases, Huntersville
Infectious Disease Specialists of Atlanta (IDSA), Decatur
Orlando Immunology Center, Orlando
Infectious Disease of Central Florida, Orlando
Treasure Coast Infectious Disease Consultants, Vero Beach
Wohlfeiler, Piperato and Associates, LLC, Miami Beach
Broward Health, Fort Lauderdale
Gary Richmond, MD, PA, Inc., Fort Lauderdale
Be Well Medical Center, Berkley
Northstar Medical Center, Chicago
Southampton Healthcare, Inc., St Louis
Health for Life Clinic, PLLC, Little Rock
Nicholaos Bellos, MD, PA, Dallas
AIDS Arms/ Peabody Health Center, Dallas
Gordon E. Crofoot, MD, PA, Houston
Apex Research Institute, Denver
Southwest C.A.R.E. Center, Santa Fe
Peter J. Ruane, MD, Inc., Los Angeles
The Living Hope Foundation, Long Beach
Orange Coast Medical Group, Newport Beach
Metropolis Medical, San Francisco
East Bay AIDS Center, Oakland
TribalMed, Seattle
Community Research Initiative of New England, Boston
Lead Sponsor
Gilead Sciences
INDUSTRY